1-6 of 6
Yvonne Gasior, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Kiyomi Morita, MDPhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Naval Daver, MD, Elias Jabbour, MD, Yesid Alvarado, MD, Kelly S. Chien, MD, Courtney D. DiNardo, MD MSCE, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kiran Naqvi, MD MPH, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Caitlin R. Rausch, PharmD, Yvonne Gasior, RN, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–9.
https://doi.org/10.1182/blood-2020-142003
Published: 2020
Journal Articles

Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab

Caitlin R. Rausch, PharmD, Shilpa Paul, PharmD, Guillermo Montalban Bravo, MD, Elias J. Jabbour, MD, Naval G. Daver, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSc, Farhad Ravandi, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kiran Naqvi, MD MPH, Steven M. Kornblau, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Maro N. Ohanian, DO, Sherry A. Pierce, BSN, BA, Yvonne Gasior, RN, Christopher B. Benton, MD, Nitin Jain, MD, Koichi Takahashi, MD, Lucia Masarova, MD, Michael Andreeff, MD PhD, Zeev E. Estrov, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4367.
https://doi.org/10.1182/blood-2018-99-116714
Published: 2018
Journal Articles

Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Naval G. Daver, MD, Elias J. Jabbour, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSc, Farhad Ravandi, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kiran Naqvi, MD MPH, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Caitlin R. Rausch, PharmD, Yvonne Gasior, RN, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1831.
https://doi.org/10.1182/blood-2018-99-118948
Published: 2018
Journal Articles

Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study

Nicholas J Short, MD, Hagop M. Kantarjian, MD, Sanam Loghavi, MD, Xuelin Huang, PhD, Wei Qiao, PhD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Maro N. Ohanian, DO, Courtney D. DiNardo, MDMSc, Zeev E. Estrov, MD, Rashmi Kanagal-Shamanna, MD, Abhishek Maiti, MBBS, Christopher B. Benton, MD, Prithviraj Bose, MD, Yesid Alvarado, MD, Elias J. Jabbour, MD, Steven M. Kornblau, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Yvonne Gasior, RN, Mary Ann Richie, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 84.
https://doi.org/10.1182/blood-2018-99-115367
Published: 2018
Journal Articles

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Guillermo Montalban-Bravo, MD, Naval G. Daver, MD, Elias J. Jabbour, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD, MSc, Farhad Ravandi, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kiran Naqvi, MD, MPH, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD, PhD, Simona Colla, PhD, Hui Yang, PhD, MD, Caitlin R. Rausch, PharmD, Yvonne Gasior, RN, Carlos E. Bueso-Ramos, MD, PhD, Rashmi Kanagal-Shamanna, MD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 465.
https://doi.org/10.1182/blood-2018-99-119424
Published: 2018
Journal Articles

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Rita Assi, MD, Prithviraj Bose, MD, Srdan Verstovsek, MD PhD, Yvonne Gasior, RN, Nitin Jain, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MDMSc, Naveen Pemmaraju, MD, Steven Kornblau, MD, Tapan Kadia, MD, Naval Daver, MD, Mark Brandt, BS, Sherry Pierce, BSN, BA, Xuelin Huang, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1379.
https://doi.org/10.1182/blood.V130.Suppl_1.1379.1379
Published: 2017